Technical Analysis for ABEO - Abeona Therapeutics Inc.

Grade Last Price % Change Price Change
grade F 2.23 -3.88% -0.09
ABEO closed down 3.88 percent on Monday, November 18, 2019, on 28 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ABEO trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -3.88%
20 DMA Resistance Bearish -1.76%
MACD Bearish Centerline Cross Bearish -1.76%
Stochastic Reached Oversold Weakness -1.76%
Oversold Stochastic Weakness -1.76%
20 DMA Resistance Bearish -4.29%
Pocket Pivot Bullish Swing Setup -4.29%

Older signals for ABEO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).
Biotechnology Biology Emerging Technologies Gene Therapy Molecular Biology Genetics Genetic Engineering Genome Editing Adeno Associated Virus AAV Cas9 CRISPR Severe And Rare Diseases
Is ABEO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.55
52 Week Low 1.46
Average Volume 509,548
200-Day Moving Average 4.8623
50-Day Moving Average 2.5372
20-Day Moving Average 2.463
10-Day Moving Average 2.457
Average True Range 0.2125
ADX 14.99
+DI 15.5945
-DI 19.9886
Chandelier Exit (Long, 3 ATRs ) 2.1425
Chandelier Exit (Short, 3 ATRs ) 2.7475
Upper Bollinger Band 2.7568
Lower Bollinger Band 2.1692
Percent B (%b) 0.1
BandWidth 23.857085
MACD Line -0.0394
MACD Signal Line -0.0072
MACD Histogram -0.0322
Fundamentals Value
Market Cap 89.84 Million
Num Shares 40.3 Million
EPS -0.61
Price-to-Earnings (P/E) Ratio -3.66
Price-to-Sales 831.55
Price-to-Book 7.87
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.38
Resistance 3 (R3) 2.39 2.35 2.36
Resistance 2 (R2) 2.35 2.31 2.35 2.35
Resistance 1 (R1) 2.29 2.29 2.27 2.28 2.34
Pivot Point 2.25 2.25 2.24 2.25 2.25
Support 1 (S1) 2.19 2.21 2.17 2.18 2.12
Support 2 (S2) 2.15 2.19 2.15 2.11
Support 3 (S3) 2.09 2.15 2.11
Support 4 (S4) 2.08